A Short Cognitive and Neuropsychiatric Assessment Scale for Progressive Supranuclear Palsy.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Porsche Sonja, Klietz Martin, Greten Stephan, Piot Ines A, Jensen Ida, Wegner Florian, Ye Lan, Krey Lea, Höllerhage Matthias, Pötter-Nerger Monika, Zeitzschel Molly, Hagena Keno, Kassubek Jan, Süß Patrick, Winkler Jürgen, Berg Daniela, Paschen Steffen, Tönges Lars, Gruber Doreen, Gandor Florin, Jost Wolfgang H, Kühn Andrea A, Claus Inga, Warnecke Tobias, Pedrosa David J, Eggers Carsten, Trenkwalder Claudia, Classen Joseph, Schwarz Johannes, Schnitzler Alfons, Krause Patricia, Schneider Anja, Brandt Moritz, Falkenburger Björn, Zerr Inga, Bähr Mathias, Weidinger Endy, Levin Johannes, Katzdobler Sabrina, Düzel Emrah, Glanz Wenzel, Teipel Stefan, Kilimann Ingo, Prudlo Johannes, Gasser Thomas, Brockmann Kathrin, Spottke Annika, Esser Anna, Petzold Gabor C, Respondek Gesine, Höglinger Günter U
Аннотация
OBJECTIVES: To create and validate a new scale for cognitive and neuropsychiatric impairment in PSP.
METHODS: The Short Cognitive and Neuropsychiatric (ShoCo) scale was developed containing five items (bradyphrenia, apathy, aphasia, dysexecution and disinhibition). Each item can be categorized into 0 = no deficit, 1 = mild deficit, 2 = moderate deficit and 3 = severe deficit. The total score includes 15 points, 0 meaning no deficit and 15 severe deficits. Cross-sectional and longitudinal data from 201 baseline and 71 follow up patients were analyzed.
RESULTS: Baseline ShoCo scale results were 5.9 ± 2.9. No significant differences between patients with Richardson syndrome (PSP-RS) and variants (vPSP) could be detected in the PSP-ShoCo scale scores (PSP-RS 6.1 ± 3.0, n = 160, vPSP 5.1 ± 2.6, n = 41, P = 0.057). The scale showed good correlation with established scores (eg, Montreal cognitive assessment r = -0.535, P = 0.001). The ShoCo scale showed significant annualized change within the PSP-RS patients (baseline 6.2 ± 2.9, follow up 6.9 ± 3.1, annualized diff. 1.0 ± 3.1, n = 57, P = 0.022).
CONCLUSIONS: The ShoCo scale seems a promising and valid tool to measure specific neuropsychological disabilities of PSP patients in clinical routine and research.